Peanut Allergy Immunotherapy: A Year in Review is organized by Medscape, LLC.
CME Released: 1/31/2019
Valid for credit through: 1/31/2020
• Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™
Target Audience and Goal Statement:
This activity is intended for allergists and clinical immunologists, primary care physicians, and pediatricians.
The goal of this activity is to educate clinicians on the novel developments and the latest trailblazing data from recent phase 3 clinical trials on peanut allergy immunotherapy.
Upon completion of this activity, participants will:
• Have increased knowledge regarding the
• Key developments in peanut allergy immunotherapy research reported in 2018
• Potential implications of clinical data from phase 3 trials of peanut allergy immunotherapies
Additional details will be posted as soon as they are available.
Pediatrics Allergy and Immunology